key: cord-0931180-vr03orz6 authors: Machado, Marina; Valerio, Maricela; Álvarez‐Uría, Ana; Olmedo, María; Veintimilla, Cristina; Padilla, Belén; De la Villa, Sofía; Guinea, Jesús; Escribano, Pilar; Ruiz‐Serrano, María Jesús; Reigadas, Elena; Alonso, Roberto; Guerrero, José Eugenio; Hortal, Javier; Bouza, Emilio; Muñoz, Patricia title: Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity date: 2020-11-29 journal: Mycoses DOI: 10.1111/myc.13213 sha: 4c168423d4f094fd5955c55ff8c187a8bb7be52b doc_id: 931180 cord_uid: vr03orz6 OBJECTIVES: Information on the recently COVID‐19‐associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID‐19), and review the published literature from Western countries. METHODS: Prospective study (March to May, 2020) that included all COVID‐19 patients admitted to a tertiary hospital. Modified AspICU and European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria were used. RESULTS: COVID‐19‐associated pulmonary aspergillosis was diagnosed in eight patients (3.3% of 239 ICU patients), mostly affected non‐immunocompromised patients (75%) with severe acute respiratory distress syndrome (ARDS) receiving corticosteroids. Diagnosis was established after a median of 15 days under mechanical ventilation. Bronchoalveolar lavage was performed in two patients with positive Aspergillus fumigatus cultures and galactomannan (GM) index. Serum GM was positive in 4/8 (50%). Thoracic CT scan findings fulfilled EORTC/MSG criteria in one case. Isavuconazole was used in 4/8 cases. CAPA‐related mortality was 100% (8/8). Compared with colonised patients, CAPA subjects were administered tocilizumab more often (100% vs. 40%, p = .04), underwent longer courses of antibacterial therapy (13 vs. 5 days, p = .008), and had a higher all‐cause mortality (100% vs. 40%, p = .04). We reviewed 96 similar cases from recent publications: 59 probable CAPA (also putative according modified AspICU), 56 putative cases and 13 colonisations according AspICU algorithm; according EORTC/MSG six proven and two probable. Overall, mortality in the reviewed series was 56.3%. CONCLUSIONS: COVID‐19‐associated pulmonary aspergillosis must be considered a serious and potentially life‐threatening complication in patients with severe COVID‐19 receiving immunosuppressive treatment. Coronavirus disease 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS), usually admitted to intensive care units (ICUs), frequently receive corticosteroids, broad-spectrum antibiotics and immunomodulatory agents. Under these circumstances, it is not surprising that the patients develop secondary complications like invasive pulmonary aspergillosis (IPA). A new term has been coined for this condition: COVID-19-associated pulmonary aspergillosis (CAPA). COVID-19-associated pulmonary aspergillosis has been described to occur in patients that do not fulfil typical risk factors for IPA (such as underlying haematological malignancy or neutropenia). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The criteria described by Blot In this work, we aim to report a series of eight CAPA cases among our COVID-19 patients, review other cases reported in literature, and compare invasive and colonisation episodes. This study was conducted at a tertiary hospital in Madrid (Spain) during the COVID-19 pandemic, between March 1 and May 31, 2020. The normal capacity of our hospital is 1200 beds, 67 in adults ICUs. With the pandemic, the number of beds was increased to 1572 beds in hospitalisation areas and 135 adult ICU beds. Diseases has maintained a surveillance and registry of invasive fungal infections and an antifungal stewardship programme since 2010. We carried out a prospective single-centre, observational study. Every COVID-19 adult patient with suspected IPA, based on the isolation of Aspergillus spp. from one or more respiratory samples, were followed-up and classified as proven/probable/putative aspergillosis or colonisation. Clinical records were reviewed, including demographic, clinical and radiological features, treatment and outcomes. The number of IPA cases during the COVID-19 pandemic was compared to the previous incidence at our centre. Finally, we reviewed the literature regarding CAPA cases in which enough individual data were reported. 19 In non-immunocompromised patients, the modified AspICU algorithm was used. 20 Accordingly, patients could be classified as: 1. Proven aspergillosis: idem to EORTC/MSG criteria. 19 2. Putative aspergillosis: all four criteria had to be met: (i) Aspergillus-positive lower respiratory tract culture; (ii) compatible signs and symptoms-one or more of the following: fever refractory to at least three days of appropriate antibiotic therapy, recrudescent fever after a period of defervescence, pleuritic chest pain, pleuritic rub, dyspnoea, haemoptysis, worsening respiratory insufficiency despite appropriate antibiotic therapy and ventilatory support; (iii) abnormal chest X-ray or computed tomography (CT) scan; (iv) either presence of host risk factorsone of the following (neutropenia, underlying haematological or oncological malignancy, glucocorticoid treatment with prednisone equivalent >20 mg/day, congenital or acquired immuno- Based on the literature, we accepted COVID-19-induced ARDS as a host risk factor. 7 Aspergillus colonisation: Isolation of Aspergillus spp. in one or more respiratory samples for which the former criteria was not fulfilled. Acute respiratory distress syndrome diagnosis was based on the Berlin definition 21 which requires the occurrence of timing, radiological, and clinical criteria. COVID-19-associated pulmonary aspergillosis-related mortality was defined as death with current signs of IPA. 22 Obesity was defined as a body mass index >25 kg/m 2 . antifungal therapy, Aspergillus infection, COVID-19, fungal diseases, fungal infections, intensive care, invasive pulmonary aspergillosis, SARS-CoV-2 infection Presence of SARS-CoV-2 in respiratory samples was confirmed by RT-PCR (TaqManTM 2019-nCoV Assay; Applied Biosystems). the Wako β-glucan test (Fujifilm Wako Pure Chemical Corporation). A cut-off value of 11 pg/mL was used. GM testing was performed using Platelia™ Aspergillus (Bio-Rad Laboratories) with a cut-off value of ≥0.5 in serum and ≥1.0 in BAL. Serum GM and BDG were performed in cases of suspected fungal infection. Culture of respiratory samples was performed upon clinical request on Sabouraud dextrose agar and BHI (Brain Heart Infusion) agar. Selected isolates -one isolate per species and patient -were molecularly identified after amplification and further sequencing of the beta-tubulin gene. 23 Antifungal susceptibility testing to amphotericin B, itraconazole, voriconazole, posaconazole (Sigma-Aldrich), and isavuconazole (Basilea Pharmaceutica International Ltd.) was performed according to EUCAST 9.3.2 methodology. 24 Resistant isolates defined based on updated 2020 EUCAST breakpoints. 25 Clinical records were recorded onto a data collection form and To detect significant differences between groups, the Mann-Whitney U test for continuous variables and χ 2 or Fisher's exact test (when at least one expected frequency in a fourfold table is less than five) for categorical variables were used. The study was approved by the Research Ethics Committee with Medicines of Hospital General Universitario Gregorio Marañón (study MICRO.HGUGM.2020-027) and granted a waiver of informed consent from study participants. During the study period, 2723 patients were admitted to our hospitalisation wards and of those, 239 to ICUs (8.7%) due to COVID-19. The characteristics of the eight CAPA patients are detailed in Table 1 Previous or concomitant bacterial and/or viral infections were found in 5/8 patients (62.5%), as described in Table 1 . All patients received antimicrobials and corticosteroids (≥20 mg/day of prednisone All CAPA patients were admitted to the ICU. Thus, we compared the characteristics of the eight CAPA patients with the five COVID-19 patients also in the ICU but who were only colonised by Aspergillus spp. (AC) ( We believe that our figure of 3.3% reflects more accurately current CAPA incidence. The physiopathology of CAPA infection remains undetermined. Immune dysregulation associated with ARDS 31 or its treatment (tocilizumab, corticosteroids) may predispose to infections with opportun- ists. 32 A recent study 33 showing ground-glass opacities, a crazy-paving pattern and patchy consolidations. 40 As described in Table 3 Dr Muñoz reports personal fees from PFIZER, personal fees from GILEAD, outside the submitted work Dr Hortal and Dr Bouza declare no conflicts of interest Conceptualization (equal) Formal analysis (lead) Investigation (equal) Writing-original draft (lead) Writing-review & editing (equal) Conceptualization (equal) Ana Álvarez-Uría: Investigation (equal) Jesus Vicente Guinea Ortega: Investigation (equal) Pilar Escribano: Investigation (equal) Elena Reigadas: Investigation (supporting) Roberto Alonso: Investigation (equal) Javier Hortal: Resources (equal). Emilio Bouza: Supervision (supporting) Writing-review & editing (supporting) Supervision (lead) Writing-review & editing (supporting) Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital Is the COVID-19 pandemic a good time to include Aspergillus molecular detection to categorize aspergillosis in ICU patients? A monocentric experience COVID-19-associated invasive pulmonary aspergillosis COVID-19-associated pulmonary aspergillosis COVID-19 associated pulmonary aspergillosis Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -a case report. Med Mycol Case Rep Clinical and virological data of the first cases of COVID-19 in Europe: a case series Azoleresistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: a diagnostic challenge COVID-19 associated pulmonary aspergillosis (CAPA): an Australian case report. Med Mycol Case Rep Multi-triazoleresistant Aspergillus fumigatus and SARS-CoV-2 co-infection: a lethal combination Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. Med Mycol Case Rep Confirmed invasive pulmonary aspergillosis and COVID-19: the value of postmortem findings to support antemortem management Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study Acute respiratory distress syndrome: the Berlin Definition Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to Is azole resistance in Aspergillus fumigatus a problem in Spain? EUCAST DEFINITIVE DOCUMENT E.DEF 9.3.2. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds Breakpoint tables for interpretation of MICs for antifungal agents, version 10 Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series Intensive care management of influenza-associated pulmonary aspergillosis The acute respiratory distress syndrome: from mechanism to translation Can steroids reverse the severe COVID-19 induced "cytokine storm COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies Invasive fungal diseases during COVID-19: we should be prepared Invasive aspergillosis as an under recognized superinfection in COVID-19 Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management Imaging features of coronavirus disease 2019 (COVID-19): evaluation on thin-section CT High-resolution computed tomography and pathologic findings in pulmonary aspergillosis: a pictorial essay Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease Diagnosing COVID-19-associated pulmonary aspergillosis Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity The authors are grateful to Dainora Jaloveckas for editing assistance.The Gregorio Marañón Microbiology-ID COVID 19 Study Group: The data that support the findings of this study are available from the corresponding author upon reasonable request.